First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. JanjigianGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USAKohei ShitaraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: [email protected]Markus MoehlerDepartment of Medicine, Johannes-Gutenberg University Clinic, Mainz, GermanyMarcelo GarridoPamela SalmanDepartment of Medical Oncology, Oncovida Cancer Center, Fundación Arturo López Pérez, Providencia, ChileLin ShenDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing, Peking University Cancer Hospital and Institute, Beijing, ChinaLucjan WyrwiczKlinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warsaw, PolandKensei YamaguchiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, JapanTomasz SkoczylasII Klinika Chirurgii Ogólnej, Gastroenterologicznej i Nowotworów Układu Pokarmowego, Medical University of Lublin, Lublin, PolandArinilda Campos BragagnoliDepartment of Medical Oncology, Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, BrazilTianshu LiuDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, ChinaMichael SchenkerPatricio YañezDepartment of Internal Medicine, Oncology Unit, Universidad de La Frontera, Temuco, ChileMustapha TehféHematology-Oncology, Oncology Center-Centre Hospitalier de l'Universite de Montreal, Montreal, QC, CanadaRubén Dario KowalyszynMichalis V. KaramouzisDepartment of Biological Chemistry and Laiko General Hospital Medical School, National and Kapodistrian University of Athens, Athens, GreeceRicardo BrugésInternal Medicine, Clinical Oncology, Instituto Nacional de Cancerología Empresa Social del Estado, Bogotá, ColombiaThomas ZanderDepartment of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düesseldorf, University Hospital of Cologne, Cologne, GermanyRoberto Pazo-CidDepartment of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, SpainErika HitreDepartment of Chemotherapy, National Institute of Oncology, Budapest, HungaryKynan FeeneyDepartment of Oncology, Haematology and Palliative Care, St John of God Murdoch Hospital, Murdoch, WA, AustraliaJames M. ClearyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAValerie PoulartBristol Myers Squibb, Princeton, NJ, USADana CullenBristol Myers Squibb, Princeton, NJ, USAMing LeiBristol Myers Squibb, Princeton, NJ, USAHong XiaoBristol Myers Squibb, Princeton, NJ, USAKaoru KondoBristol Myers Squibb, Princeton, NJ, USAMingshun LiBristol Myers Squibb, Princeton, NJ, USAJaffer A. AjaniDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2021en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0